SG11202103389WA - Immunogenic compositions - Google Patents

Immunogenic compositions

Info

Publication number
SG11202103389WA
SG11202103389WA SG11202103389WA SG11202103389WA SG11202103389WA SG 11202103389W A SG11202103389W A SG 11202103389WA SG 11202103389W A SG11202103389W A SG 11202103389WA SG 11202103389W A SG11202103389W A SG 11202103389WA SG 11202103389W A SG11202103389W A SG 11202103389WA
Authority
SG
Singapore
Prior art keywords
immunogenic compositions
immunogenic
compositions
Prior art date
Application number
SG11202103389WA
Inventor
Mario Contorni
Mariagrazia Pizza
Anja Seubert
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of SG11202103389WA publication Critical patent/SG11202103389WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/5555—Muramyl dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
SG11202103389WA 2018-11-06 2019-11-04 Immunogenic compositions SG11202103389WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18204691 2018-11-06
PCT/EP2019/080120 WO2020094580A1 (en) 2018-11-06 2019-11-04 Immunogenic compositions

Publications (1)

Publication Number Publication Date
SG11202103389WA true SG11202103389WA (en) 2021-05-28

Family

ID=64456746

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202103389WA SG11202103389WA (en) 2018-11-06 2019-11-04 Immunogenic compositions

Country Status (14)

Country Link
US (1) US20230201325A1 (en)
EP (1) EP3876982A1 (en)
JP (1) JP7469302B2 (en)
KR (1) KR20210090646A (en)
CN (1) CN112996538A (en)
AR (1) AR117191A1 (en)
AU (1) AU2019376832B2 (en)
BR (1) BR112021007668A2 (en)
CA (1) CA3117867A1 (en)
EA (1) EA202190914A1 (en)
IL (1) IL282753A (en)
MX (1) MX2021005303A (en)
SG (1) SG11202103389WA (en)
WO (1) WO2020094580A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240082379A1 (en) 2020-12-11 2024-03-14 Glaxosmithkline Biologicals Sa Hyper-Blebbing Bacteria
GB202211033D0 (en) 2022-07-28 2022-09-14 Glaxosmithkline Biologicals Sa Purification process

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2848965A1 (en) 1978-11-11 1980-05-22 Behringwerke Ag METHOD FOR PRODUCING MEMBRANE PROTEINS FROM NEISSERIA MENINGITIDIS AND VACCINE CONTAINING THEM
DE69022106T2 (en) 1989-04-28 1996-02-15 Sclavo Spa Pertussis toxin mutants, the same producing Bordetella strains and their use as a vaccine against pertussis.
DE122007000087I1 (en) 1998-10-16 2008-03-27 Glaxosmithkline Biolog Sa ADJUVANCY SYSTEMS AND VACCINES
IL144084A0 (en) 1999-02-03 2002-05-23 Biosante Pharmaceuticals Inc Therapeutic calcium phosphate particles and methods of manufacture and use
EP1034792A1 (en) 1999-03-11 2000-09-13 Pasteur Merieux Serums Et Vaccins Intranasal delivery of pneumococcal polysaccharide vaccines
FR2791895B1 (en) 1999-03-23 2001-06-15 Pasteur Merieux Serums Vacc USE OF TREHALOSE TO STABILIZE A LIQUID VACCINE
ES2307553T3 (en) 1999-12-02 2008-12-01 Novartis Vaccines And Diagnostics, Inc. COMPOSITIONS AND PROCEDURES TO STABILIZE BIOLOGICAL MOLECULES AFTER LIOPHILIZATION.
NO20002828D0 (en) 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinaceous vaccine against Neisseria meningtidis serogroup and method of preparation thereof
WO2003009869A1 (en) 2001-07-26 2003-02-06 Chiron Srl. Vaccines comprising aluminium adjuvants and histidine
CA2493124C (en) * 2002-08-02 2014-04-29 Glaxosmithkline Biologicals S.A. Vaccine
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
ES2642138T3 (en) * 2011-12-21 2017-11-15 Bionet-Asia Co. Ltd Strains of Bordetella pertussis modified
CN104717977A (en) * 2012-10-03 2015-06-17 诺华股份有限公司 Immunogenic composition
EA030749B1 (en) 2013-03-08 2018-09-28 Янссен Вэксинс Энд Превеншн Б.В. Acellular pertussis vaccine
AR090538A1 (en) * 2013-03-27 2014-11-19 Consejo Nac Invest Cient Tec VACCINE FOR THE PREVENTION OF INFECTIONS WITH BORDETELLA
CA2919773A1 (en) 2013-08-05 2015-02-12 Glaxosmithkline Biologicals S.A. Combination immunogenic compositions

Also Published As

Publication number Publication date
EP3876982A1 (en) 2021-09-15
JP2022506347A (en) 2022-01-17
AU2019376832B2 (en) 2024-01-25
MX2021005303A (en) 2021-07-07
AR117191A1 (en) 2021-07-21
JP7469302B2 (en) 2024-04-16
BR112021007668A2 (en) 2021-07-27
CA3117867A1 (en) 2020-05-14
KR20210090646A (en) 2021-07-20
EA202190914A1 (en) 2021-08-03
CN112996538A (en) 2021-06-18
WO2020094580A1 (en) 2020-05-14
IL282753A (en) 2021-06-30
AU2019376832A1 (en) 2021-05-13
US20230201325A1 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
GB201811312D0 (en) Compositions
GB2586745B (en) Compositions
SG11202010821TA (en) Vaccine composition
GB201802339D0 (en) Immunogenic composition
GB201711635D0 (en) Immunogenic composition
SG11202104306XA (en) Compositions
SG11202009259VA (en) Compositions
IL274975A (en) Immunostimulatory compositions
GB201711637D0 (en) Immunogenic composition
IL291559A (en) Immunogenic compositions
IL282753A (en) Immunogenic composition
GB201803923D0 (en) Compositions
GB2562241B (en) Vaccine compositions
IL271603A (en) Immunogenic compositions
SG11202009147UA (en) Vaccine compositions
GB201604755D0 (en) Immunogenic compositions
GB201803692D0 (en) Immunogenic composition
GB201819206D0 (en) Novel compositions
EP3710051A4 (en) Vaccine compositions
GB2570649B (en) Compositions
GB201805676D0 (en) Compositions
GB201820010D0 (en) Immunogenic composition
GB201809541D0 (en) Vaccine compositions
GB201805393D0 (en) Vaccine compositions
ZA202005658B (en) Compositions